Leukaemia Trial, Recruiting NCT05842603 Sponsor: Massachusetts General Hospital Condition: Leukaemia
Back to Leukaemia

Leukaemia Trial, Recruiting

NCT05842603
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 18 years of age or older
  • People who have been diagnosed with a type of blood condition called a myeloproliferative neoplasm (MPN) — this includes essential thrombocythemia (ET), polycythemia vera (PV), early-stage myelofibrosis (pre-MF), myelofibrosis (MF), or a related condition not fitting a specific category (MPN NOS). For people with myelofibrosis specifically, only those whose disease is rated as "low" or "intermediate-1" risk using a standard medical scoring system (called DIPSS) are eligible. For all other MPN types, any risk level may be eligible.
  • People who are generally well enough to carry out light physical activity with little to no restriction (this is measured using a standard scale called ECOG, with a score of 0 or 1)
  • People who have at least one of the following heart or blood vessel risk factors: a body mass index (BMI) over 25, high blood pressure, high cholesterol, diabetes or pre-diabetes, metabolic syndrome, or a past history of heart disease, mini-stroke (TIA), stroke, or problems with blood vessels in the legs or arms. People who do not have any of these risk factors may still be considered, but the trial's lead doctor would need to give special approval first.

Who may not be able to join:

  • People with myelofibrosis whose disease is rated "intermediate-2" or "high" risk using the DIPSS scoring system
  • People whose general health and ability to do daily activities is significantly limited (an ECOG score above 2)
  • People with an injury or health condition that their treating doctor determines would make it unsafe for them to exercise

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Gabriela Hobbs, MD, Massachusetts General Hospital

Phone: 617-724-1124

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 March 2024
Est. completion
1 January 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Number of Participants that Complete at Least 9 Weeks of the 12 week Program

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov